Cognitive & Nootropic Peptides

Many cognitive peptides work by increasing brain-derived neurotrophic factor (BDNF) — a protein critical for neuron survival, synaptic plasticity, and memory formation. BDNF supports long-term potentiation (LTP), the molecular basis of learning. Other mechanisms include CREB (cAMP response element-binding protein) activation for gene expression related to memory consolidation, NGF (nerve growth factor) modulation for cholinergic neuron support, and direct modulation of glutamatergic, dopaminergic, or serotonergic neurotransmission.

Semax — a synthetic analogue of ACTH(4-10) approved in Russia for cognitive disorders and stroke recovery. Increases BDNF, improves attention and memory in clinical studies. Administered intranasally. Selank — a synthetic analogue of tuftsin with anxiolytic and nootropic properties, approved in Russia. Modulates GABA, serotonin, and BDNF. Dihexa — a hexapeptide angiotensin IV analogue shown to be approximately 10 million times more potent than BDNF at promoting dendritic spinogenesis in animal models. Extremely early-stage research. Cerebrolysin — a mixture of neurotrophic peptides derived from pig brain, approved in multiple countries for stroke, TBI, and dementia. Has the most clinical trial data of any cognitive peptide. PE-22-28 — a synthetic fragment of spadin that modulates TREK-1 potassium channels, studied for antidepressant-like effects in animal models.

Cognitive peptides face the challenge of crossing the blood-brain barrier (BBB). Intranasal administration is the most common approach for research peptides like Semax and Selank, as the nasal mucosa provides a partial bypass to the BBB through the olfactory epithelium. Bioavailability varies widely (2-30%) depending on the peptide, formulation, and individual anatomy. Cerebrolysin is administered intravenously. Subcutaneous injection is used for some peptides but CNS penetration is generally lower than intranasal for small peptides.

Cerebrolysin has the most robust evidence with multiple RCTs for stroke and dementia, though results are mixed and Western neurologists remain divided on its clinical utility. Semax and Selank have Russian-language clinical studies supporting their approved indications but limited Western peer-reviewed data. Dihexa has striking preclinical potency data but zero human studies — extrapolating from animal synaptogenesis to human cognitive enhancement requires extreme caution. Noopept (a dipeptide analogue) has moderate clinical evidence from Russian trials. The gap between animal neuroplasticity data and human cognitive performance is large, and expectations should be calibrated accordingly.